Медицинские вопросы и проблемы подростков, больных муковисцидозом

202

Towns SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75

203

Cystic Fibrosis Foundation Patient Registry: 2003 Annual Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation, 2004

204

Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30:1151-8

205

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

206

Wilschanski M, Durie PR. Patterns of Gl disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56:1153-63

207

Wilschanski M, Durie PR. Patterns of Gl disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56:1153-63

208

Durieu I, Pellet O, Simonot L et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol 1999;30:1052-6

209

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

210

Wilschanski M, Durie PR. Patterns of Gl disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56:1153-63

211

Lewindon PJ, Pereira TN, Hoskins AC et al. The role of hepatic stellate cells and transforming growth factor-|31 in cystic fibrosis liver disease. Am J Pathol 2002; 160:1705-15

212

Linblad A, Hultcrantz R, Strandvik B. Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology 1992; 16:372-81

213

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

214

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

215

Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30:1151-8

216

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

217

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

218

Lewindon PJ, Shepherd RW, Walsh M et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53:193-201

219

Mueller-Abt PR, Frawley KJ, Greer RM, Lewindon PJ. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. J Cyst Fibros 2008; 7:215-21

220

Lewindon PJ, Shepherd RW, Walsh M et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53:193-201

221

Lewindon PJ, Shepherd RW, Walsh M et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53:193-201

222

Lewindon PJ, Shepherd RW, Walsh M et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53:193-201

223

Gilmore IT Burroughs A, Murray-LyonlM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437-41

224

Ooi CY, Nightingale S, Durie P Freedman SD. Ursodeoxycholic acid in cystic fibrosis-associated liver disease. J Cyst Fibros 2012; 11:72-3

225

O'Brien SM, Campbell GR, Burke AF et al. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur J Gastroenterol Hepatol 1996; 8:477-83

226

Van de Meeberg PC, Houwen RH, Sinaasappel M et al. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997;32:369-73